36 results on '"Ohe, Y."'
Search Results
2. Impact of EGFR mutation status in patients with completely resected lung adenocarcinoma treated with adjuvant platinum-based chemotherapy.
3. Is median survival time difference a good measure of effectiveness in the individualized medicine era?
4. Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): An intergroup trial of JCOG0803/WJOG4307L.
5. Survival improvement in patients (pts) with small cell lung cancer (SCLC): A historical comparison before and after amrubicin (AMR) approval in Japan.
6. Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell lung cancer.
7. A phase II trial of zoledronic acid in combination with cisplatin and docetaxel in non-small cell lung cancer patients with bone metastases.
8. Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402.
9. Analysis of disease recurrence in the central nervous system (CNS) in patients with non-small cell lung cancer (NSCLC) after responded to gefitinib.
10. A phase I study of enzastaurin (Enz) combined with pemetrexed (Pem) in advanced non-small cell lung cancer (NSCLC)
11. Impact of revised lymph node measurement rules in the new RECIST version 1.1 on the tumor response evaluation in patients with advanced lung cancer
12. Genome-wide association scan detected candidate polymorphisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and paclitaxel (PTX)
13. Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan
14. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC)
15. Genetic polymorphisms correlate with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and paclitaxel (PTX)
16. Differences in the toxicity and efficacy in phase I studies between cytotoxic and molecular-targeted therapies
17. Randomized phase II study of sequential carboplatin/paclitaxel (CP) and gefitinib (G) in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC): Final results
18. Circulating tumor cell analysis in patients with non-small cell lung cancer
19. Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): JCOG0207
20. A randomized phase II study of sequential carboplatin/paclitaxel (CP) and gefitinib (G) in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC): Preliminary results
21. A randomized double-blind phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC
22. Evaluation of epidermal growth factor receptor (EGFR) mutations as predictive and prognostic indicators in patients with adenocarcinoma of the lung treated with conventional chemotherapy
23. Phase II study of weekly cisplatin, etoposide and irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC)
24. EGFR mutations detected by high-resolution melting analysis (HRMA) as a predictor of response and survival in non-small cell lung cancer (NSCLC) patients treated with gefitinib
25. Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC)
26. Evaluation of epidermal growth factor receptor (EGFR) mutations and gene copy numbers as predictors of clinical outcomes in Japanese patients with recurrent non-small-cell lung cancer (NSCLC) receiving gefitinib
27. Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan
28. Dose intensive chemotherapy for limited-stage (LS) small cell lung cancer (SCLC): A phase II study
29. Induction of cytochrome P450 (CYP3A4) by gefitinib in non-small cell lung cancer (NSCLC) patients
30. Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials
31. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ED-SCLC) (final report)
32. The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC)
33. Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients with chemotherapy-induced anemia
34. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors.
35. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
36. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.